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Severe hypercholesterolemia (HC) is defined as an elevation of total cholesterol (TC) due
to the increase in LDL cholesterol (LDL-C)>95th percentile or 190 mg/dl. The high values
of LDL-C, especially when it is maintained over time, is considered a risk factor for the
development of atherosclerotic cardiovascular disease (ASCVD), mostly expressed as
ischemic heart disease (IHD). One of the best characterized forms of severe HC, familial
hypercholesterolemia (FH), is caused by the presence of a major variant in one gene
(LDLR, APOB, PCSK9, or ApoE), with an autosomal codominant pattern of inheritance,
causing an extreme elevation of LDL-C and early IHD. Nevertheless, an important
proportion of serious HC cases, denominated polygenic hypercholesterolemia (PH), may
be attributed to the small additive effect of a number of single nucleotide variants (SNVs),
located along the whole genome. The diagnosis, prevalence, and cardiovascular risk
associated with PH has not been fully established at the moment. Cascade screening
to detect a specific genetic defect is advised in all first- and second-degree relatives of
subjects with FH. Conversely, in the rest of cases of HC, it is only advised to screen high
values of LDL-C in first-degree relatives since there is not a consensus for the genetic
diagnosis of PH. FH is associatedwith the highest cardiovascular risk, followed by PH and
other forms of HC. Early detection and initiation of high-intensity lipid-lowering treatment
is proposed in all subjects with severe HC for the primary prevention of ASCVD, with
an objective of LDL-C <100 mg/dl or a decrease of at least 50%. A more aggressive
reduction in LDL-C is necessary in HC subjects who associate personal history of ASCVD
or other cardiovascular risk factors.
Keywords: primary hypercholesterolemia, familial hypercholesterolemia, polygenic hypercholesterolemia,
cardiovascular disease, LDL-cholesterol, atherosclerosis
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INTRODUCTION
Severe primary hypercholesterolemia (HC) is a disorder of
lipid metabolism, clinically characterized by an elevation
of LDL cholesterol (LDL-C) >190 mg/dl and/or total
cholesterol (TC) >95th percentile or >300 mg/dl, with
normal values of triglycerides (TGs). Despite the great
efforts and health plans carried out to improve the
detection and clinical management of HC subjects, that
population still remains underdiagnosed and undertreated
(Nordestgaard et al., 2013; Representatives of the Global
Familial Hypercholesterolemia Community et al., 2020).
Classically, severe HC constitutes an inherited trait, frequently
associated with high cardiovascular risk due to lifelong
exposure to elevated cholesterol levels, causing ischemic
heart disease (IHD) as the main clinical manifestation
(Civeira and International Panel on Management of Familial
Hypercholesterolemia, 2004; Mach et al., 2020). One of the
best known cause of HC is familial hypercholesterolemia (FH)#
143890, a genetic disorder with an autosomal codominant
inheritance pattern, due to a monogenic defect in LDL
receptor (LDLR), apolipoprotein B (APOB), Proprotein
convertase subtilisin/kexin type 9 (PCSK9), or apolipoprotein
E (APOE) genes, involved in the LDL receptor endocytic and
recycling pathways.
However, a deeper knowledge about genomics has made
it possible to detect genetic variations related to a specific
trait. One of the most extended methods, genome-wide
association studies (GWAS), allows to detect hundreds of
single variations in a nucleotide (SNVs) in a unique subject,
located throughout the genome. Some of these SNVs may be
associated with differences in LDL-C serum values and IHD.
Afterwards, it makes possible to compare the same unbiased
genome screens of unrelated individuals and appropriately
matched controls. When a number of these SNVs cluster
in the same subject, it has been set out as a cause of
primary HC (Teslovich et al., 2010), being labeled as polygenic
hypercholesterolemia (PH) (Talmud et al., 2013). Nonetheless,
there still remains a proportion of HC subjects in whom
no significant increase is detected on SNVs related to LDL-
C with respect to the general population. Hitherto, the
prevalence, diagnosis, and clinical management of subjects
with PH have not been set up. The aim of this review
was to describe the clinical profile, inheritance pattern,
and treatment of subjects with PH, as well as the main
difference between monogenic and non-monogenic origen
of HC.
Abbreviations: ASCVD, atherosclerotic cardiovascular disease; DLCN, Dutch
Lipid Clinic Network; FH, familial hypercholesterolemia; GWAS, genome-wide
association study; HC, hypercholesterolemia; IHD, ischemic heart disease; LDL-
C, low-density lipoprotein cholesterol; non-HDL-C, non-HDL cholesterol; PH,
polygenic hypercholesterolemia; TC, total cholesterol; TG, triglycerides; TX,
tendinous xanthoma; SNV, single nucleotide variant.
PRIMARY HYPERCHOLESTEROLEMIA AS
A DRIVING FACTOR FOR THE
DEVELOPMENT OF CARDIOVASCULAR
DISEASE
Classically, severe HC has been established as a causal risk
factor of atherosclerotic cardiovascular disease (ASCVD) (Ross,
1999; Nordestgaard et al., 2013). However, a positive correlation
between TC and ASCVD has been observed in men and women,
as a continuous variable from TC values >180 mg/dl, whereas
a very low incidence of ASCVD has been observed in those
with TC below that value (Stamler et al., 1986; Nagasawa
et al., 2012; Kwon et al., 2019; Maihofer et al., 2020). Similarly,
the treatment with hypolipemiant drugs maintained over the
years has demonstrated a significant decrease in IHD and
cardiovascular mortality in subjects with primary HC (Besseling
et al., 2014; Humphries et al., 2018; Perez-Calahorra et al., 2019).
Recent meta-analyses of prospective cohort studies,
Mendelian randomization studies, and randomized controlled
trials, including more than 2 million of participants, allowed to
establish a log-linear, dose-dependent association between TC,
non-HDL cholesterol (non-HDL-C) and LDL-C, and the risk of
IHD and mortality (Figure 1). All of them are surrogate markers
of apolipoprotein B (ApoB), an apoprotein that transports the
majority of cholesterol in the blood stream. From among them
all, LDL-C is the best correlated to ApoB, since it contains up to
90% of all apoB detected, while in non-HDL-C and TC, a bigger
amount of TG and other lipoparticles is included (Ference et al.,
2017).
All these studies offered the possibility of establishing
a temporal association between LDL-C exposure and IHD.
However, Mendelian randomization studies go a step further
introducing a lifelong randomization scheme by the genetic
variants associated with serum LDL-C values (Ference et al.,
2012; Holmes et al., 2015) (Figure 1). The GWAS and custom
genotyping arrays, carried out in populations from European,
American, and African ancestry, have allowed to detect a number
of SNV linked up with the catabolism and overproduction
of LDL particles as well as the prevalence of IHD (Willer
et al., 2013). Each of these variants is approximately inherited
randomly at the time of conception in a process referred
as “Mendelian randomization” (Ference, 2015). If there is no
association with any other variant in other gene-modifying LDL-
C, that genetic variant should provide and estimation of the
effect on LDL-C levels. It is possible to establish a relation
between that genetic variant and the risk of ASCVD, analogously
to a long-term clinical trial. These studies have demonstrated
that only variants in genes that modify LDL-C, but not in
another traits of lipid profile, are associated with a lower risk
of IHD. Finally, randomized control trials show the reduction
in ASCVD incidence by reducing LDL-C. In a classical meta-
analysis including 170,000 subjects, a decrease of 1 mmol (38
mg/dl) of LDL-C by statins was associated with a 22% reduction
in the risk of major cardiovascular events over a median of
5 years of treatment. The magnitude of this reduction was
independent of baseline LDL-C and any type of hypolipemiant
Frontiers in Genetics | www.frontiersin.org 2 December 2020 | Volume 11 | Article 554931
Jarauta et al. Clinical Profile and Genetic Insights
FIGURE 1 | Reproduced with permission from Ference et al. (2017). Log-linear association per unit change in low-density lipoprotein cholesterol (LDL-C) and the risk
of cardiovascular disease as reported in meta-analyses of Mendelian randomization studies, prospective epidemiological cohort studies, and randomized clinical trials.
drug used, and its results are remarkably consistent in different
subgroups of patients studied [(Cholesterol Treatment Trialists’
(CTT) Collaborators et al., 2008; Wang et al., 2020)] (Figure 1).
The comparison of data from these three sources has enabled
to draw a figure relating the magnitude of LDL-c exposition
and the proportional reduction in risk of coronary heart
disease observed in the three types of studies. Interestingly,
with the same magnitude of lowering LDL-C, the biggest effect
was observed in Mendelian randomized studies, emphasizing
not only the importance of the serum values of LDL-C but
also the time of exposure, expressed as the LDL burden
for atherosclerosis (Figure 1) (Ference et al., 2017). High
serum concentration of LDL particles maintained over the
time implies a high burden of ApoB, which can cross the
endothelial barrier and interact with other wall components,
leading to the thickening of the arterial walls and the
development of atherosclerotic plaques. Some of the mechanisms
implied as vascular inflammation is related to the pathological
internalization of apoB-containing particles by macrophages,
especially when LDL particles become oxidized or are otherwise
modified (Borén et al., 2020). Those damaged plaques may evolve
to be broken, especially when it contains a necrotic core and
macrophage accumulation full of LDL particles (Ross, 1999).
Recent findings have correlated the descent in LDL-C with a
decrease in atherosclerotic plaque volume and ASCVD (Forbes
et al., 2016).
GENETICS OF PRIMARY
HYPERCHOLESTEROLEMIA: FROM
MAJOR VARIANTS IN A UNIQUE GEN TO
THE ADDITIVE EFFECTS OF SINGLE
NUCLEOTIDE VARIANTS IN MULTIPLE
GENES
A new approach to genetic diagnosis of primary HC has been
developed: from searching for new monogenic variations with
large effect on disease status, to the additive effect of several small
variants with little pathogenic effect on several genes related to
lipids metabolism in the same subject (Berberich and Hegele,
2019). The traditional definition of severe HC corresponds to
a monogenic disease in which one copy of a variant allele
produces the disease phenotype. The first cases of HC associated
with a familial pattern, tendinous xanthomas (TX), and early
mortality were reported in the 1930s by Carl Müller, based on
the findings of 17 families with xanthomata and early IHD
in Norway (Ose, 2002). It was not until the 1970s that the
identification of a variant of LDLR causing lack of affinity of LDL
particle to the LDL receptor enabled Goldstein and Brown to
establish the pathogenesis of FH (Goldstein and Brown, 1974).
Until now, more than 2,000 causative variants of FH have been
described, the majority (80%) located in LDLR and the rest
in APOB and PCSK9 genes. The effects of that allelic variants
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encompass any of the stages of receptor-mediated endocytosis of
LDL particles. The effect of large LDLR variants can be sorted out
in two categories: no protein synthesis or synthesis of a totally
non-functional receptor, whereas large APOB variants affect the
receptor-binding domain of ApoB. Finally, PCSK9 variants with
a gain of function increase the LDL-receptor recycling process,
decreasing its half-life and its availability in the cell surface. Since
all of them correspond to pathogenic variants that are expressed
with autosomal codominant inheritance pattern, they have been
grouped as causes of FH (Awan et al., 2013; Cenarro et al.,
2016; Chora et al., 2018). Recently, the p.(Leu167) polymorphism
in APOE gene has been associated with LDLR downregulation,
raising LDL plasma levels, with clear familial segregation and
the presence of TX, accounting for 3.1% subjects with PH and
negative variants in LDLR, APOB, and PCSK9 genes (Awan
et al., 2013; Cenarro et al., 2016). In an attempt to find other
new genes causing PH phenotype, a variant in signal transducer
adaptor family member 1 (STAP1) gene causing FH phenotype
was described in a large Dutch family (Fouchier et al., 2014).
However, its role in FH seems to have been discarded recently
(Hegele et al., 2020; Lamiquiz-Moneo et al., 2020).
Regarding PH, the first definition was provided by Talmud
et al. (2013). From 27 SNVs related to LDL-C serum values,
they built a score by the 12 more predictive of PH, observing
a maximum difference of 44 mg/dL in LDL-C concentration
between subjects in the highest and the lowest decile. In the
same study, 52% of HC subjects non-carriers of large variants
causing FH had a score within deciles 7–10 of SNVs distribution.
Similar findings were reproduced in populations fromWales and
Belgium (Talmud et al., 2013).
Afterwards, the same authors simplify the diagnosis of PH,
removing the least frequent or least predictive SNVs, leaving
only 6 from the initial 12, obtaining similar yields in the
diagnosis of PH. These polymorphisms were located in genes
involved in different pathways of LDL particles metabolism such
as APOB, LDLR, and APOE genes. Others, as ABCG5/8 (ATP-
binding cassette, subfamily G,member 5/8), modulate cholesterol
production by sterols hyperabsorption (Baila-Rueda et al., 2016);
meanwhile, CELSR2 (cadherin, EGF LAG 7-pass G-type receptor
2) is related to cells signaling, although its function with respect
to LDL-C metabolism is unknown (Paththinige et al., 2017). In
a group of 1,158 probands with HC and a family history of
premature ASCVD, the polygenic score built with those SNVs
was able to diagnose 36% of subjects with PH when the cutoff
value was 75th percentile in SNVs distribution. These results
were reproduced in seven cohorts of HC subjects from different
countries (Futema et al., 2015). However, when we tried to
replicate the same experiment in our population, no differences
in its prevalence between HC and normolipemic members of the
same family were observed, explaining the 6.9% of LDL-C value
in HC subjects (Lamiquiz-Moneo et al., 2017). Another large
study carried out in 5,415 subjects who belonged to the general
population included nine SNVs from genes related to LDL-C and
HDL-C metabolism (LDLR, APOB, APOE, and ABCG5/8 among
others), observing a maximum difference of 72 mg/dl between
the homozygote classes of SNVs. Despite the fact that this
score was an independent risk factor for ASCVD, the genotype
did not improve ASCVD prediction with respect to classical
cardiovascular risk factors (Kathiresan et al., 2008).
More recently, a deeper coverage of whole genome sequencing
analyses by next-generation sequency technology has enabled to
detect monogenic variants, in addition to hundreds of SNVs,
gene copy numbers, and genomic rearrangements from the
various types of DNA-sequencing and microarray data, related
to lipid metabolism and/or ASCVD (Natarajan et al., 2018).
Nevertheless, no new variants related to LDL-C have been
detected. These SNVs have been located in genes encoding
structural components of lipoproteins, lipoprotein receptors
and related proteins, enzymes, lipid transporters, lipid transfer
proteins, and activators or inhibitors of some protein function
and gene transcription. However, some of them are within or
in the vicinity of genes that are not known to be involved in
lipid metabolism. Besides, over 90% of these SNVs are located
outside the coding regions, hence will be missed in routine
exome-sequencing techniques (Paththinige et al., 2017). Each
polymorphism is associated with small but reproducible increase
in LDL-C levels, explaining the impact of each one between 0.1
and 2.5% of LDL-C serum values (Kathiresan et al., 2008; Willer
et al., 2013; Lamiquiz-Moneo et al., 2017; Trinder et al., 2020).
Because polygenic LDL-C loci are scattered throughout the
genome and segregate independently during meiosis, most
individuals have an overall balance between LDL-C-raising and
LDL-C-lowering alleles. Rare individuals at the high extreme
of polygenic scores have inherited a preponderance of LDL-
C-raising alleles (Figure 2) (Berberich and Hegele, 2019) and
frequently clustered and inherited in the same family by
mechanisms not described hitherto (Table 1) (Jarauta et al., 2016;
Berberich and Hegele, 2019). Furthermore, these SNVs seem to
contribute to the severity of HC and increased IHD in some
FH subjects that exhibit higher LDL-C levels with respect to
FH without a polygenic inheritance (Talmud et al., 2013; Ghaleb
et al., 2018; Trinder et al., 2019). Nowadays, the diagnosis of PH
varies depending on the number and type of SNVs included and
the percentage cutoff point chosen for the diagnosis, without any
standard definition for PH accepted at the moment (Table 2).
Thus, the identification of a specific genetic pathological variant
is not a necessary condition for the diagnosis of a genetic HC
(Berberich and Hegele, 2019).
ARE POLYGENIC
HYPERCHOLESTEROLEMIA AND
FAMILIAL HYPERCHOLESTEROLEMIA
CLINICALLY THE SAME OR DIFFERENT?
COMPARISON OF CRITERIA FOR
CLINICAL DIAGNOSIS, LIPID PROFILE,
AND CARDIOVASCULAR DISEASE
Recent data delivered a higher prevalence of FH than previously
documented, with a general pooled estimation in 1:250 (0.4%)
(Benn et al., 2016; Akioyamen et al., 2017) accounting about
1.7–5.6% of subjects with severe HC (Benn et al., 2012; Khera
et al., 2016; Trinder et al., 2020). On the contrary, other
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forms of HC comprise a larger proportion of individuals in
both population-based approach studies or large samples from
different genetic backgrounds: 13.7% of 1.18 million of adults
in the United States (Patel et al., 2019), about 10% of 48,781
participants in the UK Biobank cohort study (Trinder et al.,
2020), up to 7% of 67,019 subjects from the Danish general
population study (Benn et al., 2012) and 6.8% of 20,485 ASCVD-
free subjects belonging to 12 cohorts from different countries
(Khera et al., 2016) (Table 2).
Conversely, when starting from ASCVD cases, the clinical
diagnosis of FH increases significantly, being reported in 6.7%
patients suffering from first myocardial infarction (Mortensen
et al., 2016). Besides, in case of premature myocardial infarction,
differences in FH and PH prevalence disappeared. In a study
FIGURE 2 | Reproduced with permission from Berberich and Hegele (2019).
Scheme of distributions for polygenic risk scores for LDL-cholesterol (LDL-C)
levels in the general normolipidemic population (blue) and in clinically
ascertained patients with suspected familial hypercholesterolemia (FH) but no
monogenic variant in genes causing FH (red). Scores are calculated from
single nucleotide polymorphism genotypes, by simply tallying trait-raising
alleles, or scores can be further weighted according to effect sizes for the
alleles reported in genome-wide association studies.
including 626 HC patients younger than 55 years old with a
personal history of IHD, FH prevalence was doubled than PH
(43.9 vs. 21.4%), with the highest cardiovascular risk for FH
subjects with an added polygenic trait for LDL-C. In addition,
PH was not associated with an increased cardiovascular risk with
respect to those HC subjects with no associated genetic trait
for LDL-C (Trinder et al., 2019). On the contrary, in a study
including 2,041 subjects with premature onset of myocardial
infarction, prevalence of PH was 10 times higher than those
with FH, showing a similar risk for IHD between PH and FH
subjects. However, in that case, the diagnosis of PH was not
based on LDL-C serum values, rather on the 95th percentile of
6.6 million of common DNA variants associated with myocardial
infarction detected by deep coverage whole exome sequencing
(Khera et al., 2018) (Table 2).
The main clinical characteristics of FH as the extreme
elevation of LDL-C, premature ASCVD, the presence of TX,
and family history of severe HC and premature ASCVD have
been collected in several scores as predictors of FH, since genetic
diagnosis is not affordable in all cases (Representatives of the
Global Familial Hypercholesterolemia Community et al., 2020).
The most popular, the Dutch Lipid Clinic Network (DLCN)
score, classifies subjects as “unlikely FH” (score < 3), “probable
FH” (score = 3–5), “possible FH” (score = 6–8), and “definite
FH” (score > 8) (Table 3). Quite similarly, the Simon Broome
Score labels subjects as “definite FH” if LDL-C is above 190
mg/dl and they have TX and “possible FH” for those with familial
history of premature IHD besides the elevation of LDL-C. In
both of them, a higher score or the presence of TX increased
significantly the probability of FH diagnosis (Civeira et al., 2008b;
Palacios et al., 2012; Benn et al., 2016; Trinder et al., 2019).
TX constitutes nearly a pathognomonic sign of FH, increasing
the odds ratio for the diagnosis of FH (Table 3). Nonetheless,
it might be detected in some cases of sytosterolemia, an
autosomal recessive form of HC caused by defects onABCG5 and
ABCG8 genes, which increases plasma sterols absorption (Bastida
et al., 2019). TX are composed of an extravascular deposit of
TABLE 1 | Heritage pattern analysis and heritability by family-based association test in HC families non-related to FH (Jarauta et al., 2016).
Dependent
Variable
Dominant model
(number of informative trios = 55)
Recessive model
(number of informative trios = 23)
Covariates
P-value
(FBAT)
Power
(FBAT)
Heritability P-value
(FBAT)
Power
(FBAT)
Heritability
Total cholesterol 3.92E-14 0.999 0.389* 0.001 0.934 0.059* Sex, age, BMI,
APOE
Triglycerides 0.114 0.250 0.028 3.79E-06 0.999 0.178* Sex, age, BMI,
APOE
HDL cholesterol 0.600 0.855 0.118 0.047 0.124 −0.012* Sex, age, LDLc,
BMI, APOE
LDL cholesterol 2.80E-14 0.999 0.322* 0.005 0.674 0.035* Sex, age, HDLc,
BMI, APOE
BMI, body mass index; FBAT, family-based association tests; HDL, high-density lipoprotein; LDL, low-density lipoprotein; HDLc, high-density lipoprotein cholesterol; LDLc, low-density
lipoprotein cholesterol; non-FH-GH, non-familial hypercholesterolemia-genetic hypercholesterolemia.
*Statistically significant model. Variables with significant univariate association with the lipid profile were included as covariates.
Frontiers in Genetics | www.frontiersin.org 5 December 2020 | Volume 11 | Article 554931
Ja
ra
u
ta
e
t
a
l.
C
lin
ic
a
lP
ro
file
a
n
d
G
e
n
e
tic
In
sig
h
ts
TABLE 2 | Principal studies including data about prevalence of familial hypercholesterolemia and polygenic hypercholesterolemia.
Study first
author, year
N Clinical
characteristics
Time
follow-up
(years)
Number and
genes with SNVs
included for
diagnosis of PH
Prevalence of PH
(%), % of score
Prevalence of FH
(%)
ASCVD risk FH ASCVD risk
associated to PH
Kathiresan et al.
(2008)
5,414 Cardiovascular cohort
Malmö Diet and Cancer
Study
10.6 9 (APOB, PCSK9
LDLR; CETP LIPC
LPL, APOE,
HMGCR, ABCA1)
26.2 (> fourth
quartile)
NA NA 1,63 hazard ratio
Willer et al. (2013) 1,158 PrH in proband plus
family history of
premature myocardial
infarction
NA 6 (CELSR2,
APOB, ABCG5/8
LDLR and APOE)
36 (>fourth
quartile)
351 (33,3) NA NA
Khera et al. (2016) 26,025 5,540 coronary artery
disease
NA NA NA 1.9 22 6 (HC subjects
non-FH)
Khera et al. (2018) 2,081 Early onset of
myocardial infarction
NA *6,6 × 106 17.3 (>95th
decile)
1.7 (LDLR
truncation,
frameshift,
splicing)
3.8 3.7
Benn et al. (2012) 69,016 Danish
community-based
population
NA NA 6.9 (definitive,
probable or
possible FH)
0.2 10.3 NA
Benn et al. (2016) 98,098 Copenhagen general
population Study
36 NA 7.2 0.46 5.3 LDLR carriers
1.8 APOB carriers
NA
Natarajan et al.
(2018)
16,324 From 4 ancestries** NA 2 × 106-SNV
LDL-C polygenic
score
23% of HC (>95th
decile)
2% of HC NA NA
Patel et al. (2019) 1.18 × 106 Geisinger Health
System patients
NA NA 13.7 0.15 (definitive FH) NA 1.52
Trinder et al.
(2019)
626 British Columbia FH
patients according to
DLCN, <55 yr. and
myocardial infarction
7.2 28 21.4 (>80th
percentile)
43.9 (frameshift
novel and no
sense in LDLR and
APOB mutations;
LDLR variants <
1% and
pathogenic)
1.97 1.39
Trinder et al.
(2020)
48,718 UK biobank 7.2 223 4.9 (>95th
percentile)
0.57 1.93 1.29
*Variants drawn were related to LDL-C and myocardial infarction trait.
**Subjects with lipid profile available from Framingham Heart Study (FHS), Old Order Amish (OOA), Jackson Heart Study (JHS), Multi-Ethnic Study of Atherosclerosis (MESA), FINRISK Study (FIN), and Estonian Biobank (EST).
In case that PH score study was not available, data referred as PH express the prevalence of primary hypercholesterolemia (LDL-C >95th percentile) non-related to FH. Type of event evaluated were myocardial infarction, ischemic stroke,
and death from coronary heart disease. “Definite,” “probable,” or “possible FH” was defined by the Dutch Lipid Clinic network score (>8, 6–8, 5–7, respectively). PH, polygenic hypercholesterolemia; FH, familial hypercholesterolemia;
ASCVD, atherosclerotic cardiovascular disease; SNV, single nucleotide variation; NA, non-available; NS, non-significant.
APOB, apolipoprotein B; APOE, apolipoprotein E; CELSR2, cadherin; CETP, cholesteryl ester transfer protein; EGF LAG 7-pass G-type receptor 2; HMGCR, 3-hydroxy-3-methylglutaryl-coenzyme A reductase; LDLR, low-density
lipoprotein receptor; LIPC, hepatic lipase; LPL, lipoprotein lipase; PCSK9, proprotein convertase subtilisin/kexin type 9.
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TABLE 3 | Dutch Lipid Clinic Network score criteria for diagnosis of heterozygous familial hypercholesterolemia: odds ratio of every item for the diagnosis of FH.
Points Odds ratio for FH
(Civeira et al., 2008b)
N = 825
Odds ratio for FH,
(Benn et al., 2016)
Danish General
population N =
98,098
Odds ratio for FH,
(Palacios et al., 2012)
Hypercholesterolemic
population
N = 5,430
Odds ratio for FH
%(Trinder et al.,
2019)
HC subjects <55 yr +
Myocardial infarction
-First degree relative with known
premature coronary heart disease or
1 NA 1.3(0.9–2.0)* NA NA
-First degree relative with known LDL-C
>95th percentile by age and gender for
country
1 NA 5.2(3.8–7.1)* NA NA
-First degree relative with tendon
xanthoma and/or corneal arcus or
2 7.8 NA NA NA
-Child(ren) <18 years with LDL-C > 96th
percentile by age and gender for country
2 NA NA NA NA
-Subject has premature coronary heart
disease
2 NA 3.2(1.8–5.6)* NA NA
-Subject has premature cerebral or
peripheral vascular disease
1 NA 0.8(0.3–1.9)* NA NA
Tendon Xanthoma 6 3.7 NA NA NA
Corneal arcus in a person <45 years 4 2.6 NA NA NA
LDL-C> 325 mg/dL 8 NA 138 (60–318)† NA NA
LDL-C> 251–325 mg/dL 5 NA 53(35–80)† NA NA
LDL-C>191–250 mg/dL 3 NA 53(35–80)† Na NA
LDL-C> 155–190 mg/dL 1 NA 25(19–34)† NA NA
Definite FH: DLCN >8 NA 24$ 53,9$ 74.3
Possible FH: DLCN 6–8 NA 6$ 30,7$ 37.4
Probable FH: DLCN 3–5 1,2$ 23,9$ 11.8
Unlike FH: DLCN <3 0,07$ 16,4$ NA
Table built with data from Civeira et al. (2008b), Palacios et al. (2012), Benn et al. (2016), and Trinder et al. (2019).
LDL-C denotes low density cholesterol, DLCN denotes Dutch Lipid Clinic Network. Premature coronary heart disease was considered <55 years, men; <60 years, women.
*Odds ratios for each criterion are risk of carrying a variant in individuals fulfilling the specific criteria versus those not fulfilling the same criteria used as reference group.
†
Odds ratios in groups by low-density lipoprotein (LDL)-cholesterol levels are risk of carrying a variant in genes causing FH in individuals with an LDL-cholesterol level above the threshold
compared those below.
$Percentage of subjects with pathogenic variant causing FH according to DLCN category.
LDL-C and non-cholesterol sterols (Baila-Rueda et al., 2018),
resembling the lipid composition of vascular atheromatous
plaques (Vermeer et al., 1982). The presence of TX has been
associated with early IHD independently of the genetic variant
causing FH (Civeira et al., 2005). However, the prevalence of
TX in FH subjects is only about 40% (Civeira et al., 2008b),
increasing up to 68% when sonographic evaluation is used for
the diagnosis (Junyent et al., 2005). A lower prevalence of TX
has been observed in the last decades due to long-term intensive
lipid-lowering therapy and the early diagnosis of FH (Benn et al.,
2012; Bea et al., 2017; Berberich andHegele, 2019). Consequently,
the absence of TX defines most of the subjects with HC as
“probable FH” or “possible FH” (Patel et al., 2019), decreasing the
sensitivity of DLCN and Simon Broome scores for the diagnosis
of FH (Cuchel et al., 2014; Trinder et al., 2020).
The choice of a high value of LDL-C, above 99th percentile
(>250 mg/dl), and normal values of TG is highly sensitive but
not too specific for the diagnosis of FH (Civeira and International
Panel on Management of Familial Hypercholesterolemia, 2004;
Benn et al., 2016; Trinder et al., 2019). In fact, a significant
overlap between LDL-C values in FH and PH subjects has been
observed (Figure 3) (Nordestgaard et al., 2013; Trinder et al.,
2020). Besides, most population registers are based on lipid
profile and personal history of ASCVD, whereas a familial history
of HC or ASCVD is not available (Benn et al., 2016; Khera et al.,
2016; Trinder et al., 2020). All these make more difficult to rule
out the diagnosis of FH from a clinical perspective.
Despite all of the above, FH cannot be discarded in all
cases when TGs are elevated. In 143 subjects with a clinical
diagnosis of familial combined hyperlipidemia, 19.6% carried a
variant in LDLR causing FH. This corresponds to non-diabetic
subjects with lower waist circumference and higher LDL-C
serum, without a significant difference in TG serum values
(Civeira et al., 2008a). In the same vein, a recent study including
49 families collected from 49 probands with severe HC and TG
<90th percentile ruled out a monogenic cause; up to 25% of
family members with dyslipemia had serum values of TG above
90th percentile. In addition, a polygenic nature of the disease and
the influence of environmental factors were observed, which are
expressed by the lipid profile variability and the coexistence of
different heritage patterns for TC, LDL-C, and TG in the same
family (Table 1) (Jarauta et al., 2016).
Frontiers in Genetics | www.frontiersin.org 7 December 2020 | Volume 11 | Article 554931
Jarauta et al. Clinical Profile and Genetic Insights
FIGURE 3 | Prevalence of subclinical atherosclerosis measured by carotid plaques detected by ultrasound and incidence of ASCVD in a population of 1,771 subjects
with primary hypercholesterolemia. Kaplan–Meier cumulative survival curves for patients with and without arteriosclerotic plaque in carotid arteries. 95% CI, 95%
confidence interval; HR, hazard ratio adjusted by history of cardiovascular disease, presence of carotid plaque, age, and sex.
IHD disease is the most frequent clinical expression of
ASCVD in both FH and PH patients (Benn et al., 2016; Khera
et al., 2018; Trinder et al., 2020). Nevertheless, cardiovascular risk
may vary within subjects with severe HC. In patients clinically
diagnosed as FH followed during the last 30 years, those with
“definite FH” according to Simon Broome criteria showed 2.4-
fold excess of coronary mortality, whereas the same excess risk
was 1.7 in “probable FH.” The excess risk continued being
higher in subjects with previous IHD and a genetic diagnosis
of FH despite the decrease in cardiovascular risk in the general
population and the rest of the HC population during the
same period of follow-up. Surprisingly, in the same study, the
reduction in mortality in women over three decades was less
important than the one observed inmen despite the same efficacy
observed on lowering LDL-C in men and women treated with
statins [(Cholesterol Treatment Trialists’ (CTT) Collaborators
et al., 2008)]. This fact raises the question of whether these
“definite FH” women are being treated as rigorously as their male
counterparts (Humphries et al., 2018).
Likewise, those subjects with PH present more frequently
ASCVD in other locations as cerebrovascular or peripheral
arteries and at older ages than FH. This fact has been related to the
lowermortality and the higher prevalence of other cardiovascular
risk factors observed in PH subjects (Benn et al., 2012; Perez-
Calahorra et al., 2019). Other forms of HC out of the scope
of this review, such as familial combined hyperlipidemia or
hypercholesterolemia secondary to the elevation of lipoprotein
(a), increase the risk of ASCVD with regard to the general
population (Langsted et al., 2016; Berberich and Hegele, 2019;
Luijten et al., 2019).
APPROACH FOR THE SCREENING AND
MANAGEMENT OF PRIMARY
HYPERCHOLESTEROLEMIA
The clinical significance of PH is as much as FH, since the
prevalence of severe HC and polygenic origin of disease is
more frequent in the general population (Khera et al., 2018;
Berberich and Hegele, 2019; Trinder et al., 2020). Despite the fact
that it may lead to misclassification bias for FH, the necessity
of an inclusive strategy has been considered. On the basis of
LDL-C serum values >90th percentile or >190 mg/dl in the
adulthood, it is possible to identify most patients with higher
risk for FH and ASCVD (Figure 4). The early diagnosis and
treatment of severe HC should be considered a key point to
prevent ASCVD in these subjects (Nordestgaard et al., 2013;
Humphries et al., 2018; Perez-Calahorra et al., 2019). The higher
IHD risk in FH population, especially at early ages, makes it
necessary to carry out genetic diagnosis by cascade screening
in patients clinically identified as “possible or definite FH” by
DLCN score (Benn et al., 2012; Palacios et al., 2012; Humphries
et al., 2018; Trinder et al., 2019). Nonetheless, a genetic diagnosis
of PH is not available. In addition to the difference in the
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predictive SNVs depending on the study, its prevalence is
not well-correlated to the presence of severe HC in all cases
(Lamiquiz-Moneo et al., 2017).
FIGURE 4 | Reproduced with permission from Trinder et al. (2020).
Distribution of LDL-C levels (to convert to millimoles per liter, multiply by
0.0259) at enrollment between individuals with an FH-associated variant
(mono+) and those without an FH-associated variant (mono–).
The prevalence of subclinical atherosclerosis may be a useful
method to detect those HC subjects whose ASCVD risk may
be increased. However, only a few studies comparing subclinical
atherosclerosis in FH and HC subjects are available so far.
The Coronary Artery Calcium Score was a discriminative
measurement of subclinical atherosclerosis for FH, showing
higher atherosclerotic burden for FH than other HC patients
(Sharifi et al., 2017). In a recent study, after a follow-up of 3.7
years, a 3.3-fold-higher risk of ASCVD for FHwas observed when
the calcium Agastont score was >100 with respect to those with
a calcium Agastont score = 0 (Miname et al., 2019). Besides,
the detection of atherosclerotic plaques in the carotid arteries by
ultrasound increased 2.4-fold the risk of ASCVD in 1,778 subjects
with HC, after a follow-up of 6 years (Bea et al., 2017) (Figure 5).
There is neither a case–control study to compare the effects of
lipid-lowering drugs vs. placebo for the treatment of FH subjects
nor any specific risk equations for ASCVD in this population
(Nordestgaard et al., 2013). However, statins of moderate–high
intensity, ezetimibe, and PCSK9 monoclonal antibodies have
shown a drop in the incidence of IHD and mortality in subjects
with FH or severe HC (Versmissen et al., 2008; Karatasakis et al.,
2017; Giugliano et al., 2018).
FIGURE 5 | Scheme proposed about how to manage severe primary hypercholesterolemia.
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Clinical management of PH and FH in primary prevention
does not differ from each other, since, until recently, the diagnosis
of severe HC has been based on lipid profile and history
of IHD. Consequently, there are few data for FH and PH
separately. Nonetheless, a 10 times lower odds for CVD has
been observed in HC subjects exposed to continuous lipid-
lowering treatment than in naive patients (Perez-Calahorra et al.,
2019). In another large study including patients with “definite
FH” diagnosis previously treated with statins and non-personal
history of IHD, cardiovascular risk was not greater than the
general population after 20 years of follow-up. It underlines
the clinical utility of identifying subjects with FH before they
have developed IHD and ensuring they receive intensive lipid-
lowering therapy (Humphries et al., 2018). In FH children from
10 years old and above, early treatment with moderate or high
intensity statins has reported a reduction in LDL-C between 28
and 54% with no associated secondary effects (Ramaswami et al.,
2020). The addition of ezetimibe to statins for the treatment of
HC has been shown equally effective in decreasing LDL-C in
FH children and adults (Kastelein et al., 2008; Kusters et al.,
2015).
Moreover, a different response to high-intensity statins
between FH and PH subjects has been observed. A higher
response to statins was observed in subjects with no genetic
diagnosis of FH than those with defective or null alleles, being
the last ones whom the objective of LDL-C <100 mg/dl is less
frequently achieved (47.4, 27.1, and 47.4%, respectively, p= 0.02)
(Santos et al., 2014). More recently, in a study of treatment with
high-intensity statins carried out in FH subjects, a significant
reduction in LDL-C was observed in the p.(Leu167del) carriers
on APOE (−52.1%) with respect to LDLR carriers (−39.7%) (p=
0.040) (Bea et al., 2019).
The decrease of LDL-C <100 mg/dl or at least 50% of the
basal LDL-C concentration has been advocated by observational
studies as the objective for primary prevention in populations
with severe HC (Nordestgaard et al., 2013; Mach et al., 2020).
However, this target is not attained for the greatest proportion
of HC and FH populations (Perez-Calahorra et al., 2019; Pérez
de Isla et al., 2019). Furthermore, <50% of these subjects,
particularly young ones, are in chronic treatment with a
high-intensity statin (Benn et al., 2012; Bucholz et al., 2018;
Kotseva et al., 2019; Patel et al., 2019). The addition of other
cardiovascular risk factors may modulate the intensity of the
treatment in the rest of subjects with moderate HC (Mach
et al., 2020). There is neither a minimum level of LDL-C below
which benefit has not been observed nor has been observed
a higher incidence of secondary effects associated with lower
concentrations of LDL-C. PCSK9 inhibitors, the most potent
lipid-lowering treatment available so far, reach an extra reduction
of 50–60% on LDL-C with regard to conventional treatment. It
has been proben to be effective to get LDL-C objectives in more
than 50% of FH subjects (Kastelein et al., 2015; Santos et al.,
2020), reducing the risk of cardiovascular events proportionally
in the same grade than statins (Karatasakis et al., 2017; Giugliano
et al., 2018) (Figure 1). Besides, PCSK9 inhibitors have proved to
regress atherosclerotic plaques in coronary arteries with respect
to conventional treatment in subjects with LDL-C ≤100 mg/dl
(Nicholls et al., 2016; Bea et al., 2017). Nowadays, due to the high
price of PSCK9 inhibitors, its use has only been established in
FH subjects with a very high risk or personal history of ASCVD
(Ascaso et al., 2019). Recent data suggest that only 23% of FH
subjects in treatment with moderate- to high-intensity statins
with or without ezetimibe reach LDL-C <100 mg/dl, whereas
only 12% of those with a personal history of ASCVD had LDL-
C <70 mg/dl. Nevertheless, it is estimated that only 17% of FH
subjects may be eligible for treatment with PCSK9 inhibitors,
according to current European guidelines (Masana et al., 2017).
DISCUSSION
In the last years, high-quality researches have been developed
trying to find out new genes causing primary HC. However,
no new genes other than PCSK9 and APOE have been added
to the list of those causing FH, accounting only for a small
proportion of these subjects (Nordestgaard et al., 2013; Ghaleb
et al., 2018). At the same time, a deeper knowledge about genetics
related to lipid metabolism has allowed to detect the effect of
small nucleotide variants related to LDL-C metabolism as a
new pathogenic mechanism causing primary HC (Willer et al.,
2013; Khera et al., 2016; Berberich and Hegele, 2019 (Figure 2).
Despite the description of a polygenic trait (Willer et al., 2013),
its effect has not been replicated homogeneously in a significant
proportion of subjects with severe HC, and a consensus with
respect to the diagnosis of PH has not been released so far.
There has been observed a higher cardiovascular risk in FH
with respect to PH subjects, especially at early ages (Khera
et al., 2016; Trinder et al., 2019). Moreover, the increased
cardiovascular risk associated with PH is mostly observed in
adulthood, when other cardiovascular risk factors occur in
the same subject, underlining the effect of the environment
or behavior on the phenotypic expression of genetic traits
(Humphries et al., 2018; Perez-Calahorra et al., 2019; Trinder
et al., 2020).
Despite the above facts, a large proportion of subjects with FH
remains underdiagnosed and undertreated. New strategies are
required to improve the diagnosis and treatment of HC subjects:
cascade screening on first- and second-degree relatives of an
FH proband or a more inclusive one by LDL-C measurement
of first-degree relatives from any HC proband. Early diagnosis
and treatment with moderate- to high-intensity statins result in
the best approach to primary prevention disease in HC subjects,
independently of the genetic background. Indeed, the use of high-
intensity statins for 12 years allowed to avoid 90% of ASCVD
in a large FH population (Perez-Calahorra et al., 2019). Only a
small proportion of HC subjects as those with familial history
of ASCVD or more than one risk factor associated may require
a more aggressive treatment for primary prevention of ASCVD
(Ascaso et al., 2019; Mach et al., 2020).
CONCLUSION
Severe HC is a clinical condition that constitutes an important
public health issue. Besides the genetic diagnosis of FH, new
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genetic methods have allowed to detect the additive effect of
several variants in a unique nucleotide as a cause of PH.
Nonetheless, a unique genetic criterion for the diagnosis of PH
has not been established so far. Both FH and PH are associated
with increased risk of ASCVD. The early diagnosis of severe
HC in addition to a familial history of dyslipidemia and/or
premature ASCVD is the starting point to detect those forms
of HC more related to a genetic defect and with increased
risk of ASCVD. Early treatment with high-intensity statins is
mandatory for primary prevention of ASCVD in all subjects with
severe HC.
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